Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Aina Oliver-Cáldes"'
Autor:
Anna deDaniel, Luis Gerardo Rodríguez‐Lobato, Natalia Tovar, M. Teresa Cibeira, David F. Moreno, Aina Oliver‐Caldés, Ignacio Isola, Ester Lozano, Joan Bladé, Laura Rosiñol, Carlos Fernández de Larrea
Publikováno v:
HemaSphere, Vol 8, Iss 5, Pp n/a-n/a (2024)
Abstract The 2/20/20 International Myeloma Working Group (IMWG) score is the most employed risk score in clinical practice to evaluate the risk of progression from smoldering multiple myeloma (SMM) to symptomatic multiple myeloma. However, it faces a
Externí odkaz:
https://doaj.org/article/1de8802a875642aa8d1b51cf74359b01
Autor:
Laura Martinez-Verbo, Lorea Villanueva, Pere Llinàs-Arias, Carlos Antonio García-Prieto, David Piñeyro, Aina Oliver-Caldes, Almudena García-Ortiz, Antonio Valeri, Carlos Fernández De Larrea, Joaquin Martínez-López, Gerardo Ferrer, Manel Esteller
Publikováno v:
HemaSphere, Vol 7, p e404615e (2023)
Externí odkaz:
https://doaj.org/article/3f9042ac575142cda58a8f1f53d37941
Autor:
Javier Nogués-Castell, Silvia Feu-Basilio, Óscar Felguera García, Carlos Fernández de Larrea, Aina Oliver-Caldés, Olga Balagué Ponz, Jessica Matas Fassi
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundPlasma cell leukemia (PCL) is an aggressive and rare form of plasma cell dyscrasia characterized by peripheral blood expression, poor prognosis, and high relapse rates. Extramedullary plasmacytomas are common in this entity and can affect v
Externí odkaz:
https://doaj.org/article/0e0d1ec5a3954870b2f7786d167338cc
Autor:
Raquel Jiménez-Segura, Laura Rosiñol, Ma Teresa Cibeira, Carlos Fernández de Larrea, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, Esther Bladé, David F. Moreno, Aina Oliver-Caldés, Joan Bladé
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 9, Pp 1-8 (2022)
Abstract From January 1970 to December 2018, 1304 patients were diagnosed with multiple myeloma (MM) at our institution and 256 (19.6%) had plasmacytomas (Ps) (paraskeletal –PPs- 17.6%, extramedullary –EMPs-1.9%). Patients with Ps had lower serum
Externí odkaz:
https://doaj.org/article/5e019032e0d549be9f149145a0b9acc3
Autor:
Anthony M. Battram, Aina Oliver-Caldés, Maria Suárez-Lledó, Miquel Lozano, Miquel Bosch i Crespo, Núria Martínez-Cibrián, Joan Cid, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 26, Iss , Pp 207-223 (2022)
Autologous cell immunotherapy using B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cells is an effective novel treatment for multiple myeloma (MM). This therapy has only been used for relapsed and refractory patients, at
Externí odkaz:
https://doaj.org/article/85ce7bb7085742eaa47debfe86d2dbc9
Autor:
Aina Oliver-Caldes, Juan Carlos Soler-Perromat, Ester Lozano, David Moreno, Alex Bataller, Pablo Mozas, Marta Garrote, Xavier Setoain, Juan Ignacio Aróstegui, Jordi Yagüe, Natalia Tovar, Raquel Jiménez, Luis Gerardo Rodríguez-Lobato, M. Teresa Cibeira, Laura Rosiñol, Joan Bladé, Manel Juan, Carlos Fernández de Larrea
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionMultiple myeloma (MM) is considered an incurable hematological neoplasm. For transplant-eligible patients, initial treatment includes an induction phase followed by an autologous stem cell transplantation (ASCT). Despite the introduction
Externí odkaz:
https://doaj.org/article/e5fabab14d0d45a2ac2c95f79c8116fd
Publikováno v:
European Medical Journal, Vol 2, Iss 3, Pp 121-127 (2017)
Acute lymphoblastic leukaemia (ALL) in adults has a survival rate of 40–50% at 5 years, with a high relapse rate after first-line chemotherapy. After relapse, results with salvage therapy are currently unsatisfactory. Therefore, both the optimisati
Externí odkaz:
https://doaj.org/article/59ea131376a04796baae56f50cf4f93d
Autor:
Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel, Tobias A. W. Holderried, Roland Fenk, Fabian Müller, Natalia Tovar, Aina Oliver-Cáldes, Kristin Rathje, James A. Davis, David Fandrei, Vladan Vucinic, Soraya Kharboutli, Ben-Niklas Baermann, Francis Ayuk, Uwe Platzbecker, Anca-Maria Albici, Nathalie Schub, Friederike Schmitz, Leyla Shune, Jack Khouri, Faiz Anwer, Shahzad Raza, Joseph McGuirk, Zahra Mahmoudjafari, Kimberly Green, Cyrus Khandanpour, Marcel Teichert, Barbara Jeker, Michele Hoffmann, Nicolaus Kröger, Bastian von Tresckow, Carlos Fernández de Larrea, Thomas Pabst, Al-Ola Abdallah, Nico Gagelmann
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Despite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following rel
Externí odkaz:
https://doaj.org/article/494534289884443fbc7448906d6d0a82
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.